ONO4819

Known as: ONO-4819 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2010
012320012010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Prostaglandin E(2) (PGE(2)) positively regulates bone resorption and formation mainly mediated through the EP(4) receptor, a… (More)
Is this relevant?
2010
2010
To the Editor: Prostanoids constitute a group of cyclooxygenase (COX)-derived metabolites of arachidonic acid, and include… (More)
  • figure 1
Is this relevant?
2007
2007
Bone morphogenetic proteins (BMPs) were originally isolated based on their ability to induce ectopic cartilage and bone formation… (More)
Is this relevant?
2006
2006
The effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate, a representative anti-resorptive drug, on trabecular… (More)
Is this relevant?
2005
2005
The influence of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the bone response to mechanical… (More)
Is this relevant?
2005
2005
The reduced stability of hydroxyapatite (HA)-coated implants in osteopenic conditions is considered to be a major problem. We… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
The role of prostaglandins in mechanical scratching-induced cutaneous barrier disruption in mice was investigated. Skin… (More)
Is this relevant?
2004
2004
The anabolic effects of prostaglandin E(2) on bone are effected through the activation of EP4, a G protein-coupled receptor. In… (More)
Is this relevant?
2004
2004
Indomethacin exerts a strong tocolytic effect by suppressing uterine contractions mediated by prostaglandins. However… (More)
  • figure 3
  • figure 1
  • figure 4
  • figure 2
  • table 1
Is this relevant?
2001
2001
We evaluated the efficacy of ONO-4819, a newly developed agonist of a prostaglandin receptor subtype (EP4), on experimental model… (More)
Is this relevant?